- Issuer ticker
-
ENGN
- Reported as of
-
16 Jun 2026
- Net transaction value
-
$0
- SEC form
-
4
- Accepted by SEC
-
17 Jun 2026, 17:38:11 UTC
Filing notes and source
Key filing fact
Michael Thomas Heffernan filed Form 4 for enGene Therapeutics Inc. (ENGN) on 17 Jun 2026.
Key facts
- This page summarizes Michael Thomas Heffernan's Form 4 filing for enGene Therapeutics Inc. (ENGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2026, 17:38.
Change
- Previous filing in this sequence was filed on 04 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001448914
Primary reporting owner
Heffernan Michael Thomas
- Relationship
-
Director
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENGN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +31,000
- Change %
- Price
-
$0.000000*
- Shares after
- 31,000
- Date
- 16 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 31,000
- Exercise price
- $1.75
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote